NAVB
Income statement / Annual
Last year (2022), Navidea Biopharmaceuticals, Inc.'s total revenue was $65.65 K,
a decrease of 87.65% from the previous year.
In 2022, Navidea Biopharmaceuticals, Inc.'s net income was -$15.18 M.
See Navidea Biopharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$65.65 K |
$531.51 K |
$915.01 K |
$26.62 K |
$322.52 K |
$1.81 M |
$21.97 M |
$13.25 M |
$6.27 M |
$1.13 M |
| Cost of Revenue |
$184.95 K
|
$198.83 K
|
$1.05 K
|
$6.67 K
|
$96.64 K
|
$3.65 K
|
$2.30 M
|
$1.75 M
|
$1.59 M
|
$332.82 K
|
| Gross Profit |
-$119.30 K
|
$332.68 K
|
$913.97 K
|
$19.95 K
|
$225.89 K
|
$1.81 M
|
$19.67 M
|
$11.49 M
|
$4.69 M
|
$797.82 K
|
| Gross Profit Ratio |
-1.82
|
0.63
|
1
|
0.75
|
0.7
|
1
|
0.9
|
0.87
|
0.75
|
0.71
|
| Research and Development Expenses |
$5.97 M
|
$5.14 M
|
$4.93 M
|
$5.34 M
|
$4.22 M
|
$4.51 M
|
$8.88 M
|
$12.79 M
|
$16.78 M
|
$23.71 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.96 M
|
$7.45 M
|
$6.69 M
|
$6.28 M
|
$7.70 M
|
$11.17 M
|
$13.01 M
|
$17.26 M
|
$15.54 M
|
$15.53 M
|
| Other Expenses |
$0.00
|
-$14.12 K
|
-$21.86 K
|
-$631.21 K
|
$1.15 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$13.88 M
|
$12.59 M
|
$11.63 M
|
$10.98 M
|
$11.07 M
|
$15.68 M
|
$21.90 M
|
$30.05 M
|
$32.32 M
|
$39.24 M
|
| Cost And Expenses |
$14.12 M
|
$12.59 M
|
$11.63 M
|
$10.99 M
|
$11.17 M
|
$15.69 M
|
$24.19 M
|
$31.80 M
|
$33.91 M
|
$39.57 M
|
| Interest Income |
$0.00
|
$0.00
|
$11.34 K
|
$25.29 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.10 K
|
$18.84 K
|
| Interest Expense |
$1.10 M
|
$6.36 K
|
$0.00
|
$0.00
|
$30.80 K
|
$168.97 K
|
$4.87 K
|
$1.27 M
|
$3.71 M
|
$2.78 M
|
| Depreciation & Amortization |
$95.82 K
|
$198.83 K
|
$190.58 K
|
$144.51 K
|
$150.39 K
|
$254.59 K
|
$501.37 K
|
$571.42 K
|
$500.18 K
|
$404.18 K
|
| EBITDA |
-$13.88 M |
-$11.51 M |
-$10.64 M |
-$10.82 M |
-$10.85 M |
-$13.14 M |
-$6.87 M |
-$21.31 M |
-$31.52 M |
-$38.03 M |
| EBITDA Ratio |
-211.34
|
-21.65
|
-11.63
|
-406.42
|
-33.63
|
-7.26
|
-0.31
|
-1.61
|
-5.02
|
-33.64
|
| Operating Income Ratio |
-214.02
|
-22.69
|
-11.71
|
-411.85
|
-33.63
|
-7.67
|
-0.1
|
-1.4
|
-4.4
|
-34
|
| Total Other Income/Expenses Net |
-$1.13 M
|
$345.52 K
|
-$10.51 K
|
$17.68 K
|
-$5.32 M
|
-$3.91 M
|
$2.77 M
|
-$10.32 M
|
-$13.14 M
|
-$4.26 M
|
| Income Before Tax |
-$15.18 M
|
-$11.71 M
|
-$10.72 M
|
-$10.94 M
|
-$16.17 M
|
-$17.79 M
|
-$14.31 M
|
-$28.76 M
|
-$35.73 M
|
-$42.70 M
|
| Income Before Tax Ratio |
-231.18
|
-22.04
|
-11.72
|
-411.18
|
-50.13
|
-9.83
|
-0.65
|
-2.17
|
-5.69
|
-37.77
|
| Income Tax Expense |
$0.00
|
$16.04 K
|
-$81.74 K
|
$707.00
|
$2.75 K
|
-$4.06 M
|
-$648.00 K
|
-$436.05 K
|
$2.68 M
|
$0.00
|
| Net Income |
-$15.18 M
|
-$11.73 M
|
-$10.64 M
|
-$10.95 M
|
-$16.13 M
|
$74.95 M
|
-$14.31 M
|
-$27.56 M
|
-$35.73 M
|
-$42.70 M
|
| Net Income Ratio |
-231.18
|
-22.07
|
-11.63
|
-411.21
|
-50
|
41.4
|
-0.65
|
-2.08
|
-5.69
|
-37.77
|
| EPS |
-0.59 |
-0.4 |
-0.45 |
-0.76 |
-1.89 |
9.4 |
-1.84 |
-3.65 |
-4.8 |
-7.01 |
| EPS Diluted |
-0.56 |
-0.4 |
-0.45 |
-0.76 |
-1.89 |
9 |
-1.84 |
-3.65 |
-4.8 |
-7.01 |
| Weighted Average Shares Out |
$29.34 M
|
$29.34 M
|
$23.90 M
|
$14.39 M
|
$8.53 M
|
$8.08 M
|
$7.77 M
|
$7.56 M
|
$7.44 M
|
$6.09 M
|
| Weighted Average Shares Out Diluted |
$30.90 M
|
$29.34 M
|
$23.90 M
|
$14.39 M
|
$8.53 M
|
$8.30 M
|
$7.77 M
|
$7.56 M
|
$7.44 M
|
$6.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
